Since its inception, TAVR has been one of the most exciting innovations in cardiovascular services. In recent years, TAVR has seen significant clinical advancements, leading both to better quality outcomes, and to opportunities for structural heart programs to become more efficient and cost-effective.

Indeed, with TAVR's burgeoning growth and positive forecasts for future volumes, achieving these dual aims of enhanced efficiency and high-quality outcomes will be imperative for structural heart programs to succeed.